# Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

Source: https://onco.cc/trials/nct06799637/  
OnCo record `nct06799637` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of XNW28012 in pancreatic ductal adenocarcinoma, ovarian cancer and cervical cancer, run by Evopoint Biosciences Inc., now recruiting.

## Summary

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments is a phase 1/2 interventional study registered as NCT06799637 by Evopoint Biosciences Inc., with 350 participants planned, started 2023-12-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: XNW28012.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06799637
- Phase: 1/2
- Setting: A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Efficacy of XNW28012 in Subjects With Advanced Solid Tumors
- Sponsor: Evopoint Biosciences Inc.
- Enrolled: 350

## Sources

- ClinicalTrials.gov NCT06799637: https://clinicaltrials.gov/study/NCT06799637

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Evopoint Biosciences](https://onco.cc/companies/evopoint-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct06799637.json